Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
Acute myeloid leukemia
Disseminated intravascular coagulation
Intensive chemotherapy
Khorana score
Thrombosis
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
31
08
2021
accepted:
21
01
2022
pubmed:
8
2
2022
medline:
15
3
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
The frequency of thrombosis in AML has been evaluated only in a few studies and no validated predictive model is currently available. Recently, DIC score was shown to identify patients at higher thrombotic risk. We aimed to evaluate the frequency of thromboembolism in AML patients treated with intensive chemotherapy and to assess the ability of genetic and clinical factors to predict the thrombotic risk. We performed a retrospective observational study including 222 newly diagnosed adult AML (210) and high-risk MDS (12), treated with intensive chemotherapy between January 2013 and February 2020. With a median follow-up of 44 months, we observed 50 thrombotic events (90% were venous, VTE). The prevalence of thrombosis was 22.1% and the 6-months cumulative incidence of thrombosis was 10%. The median time to thrombosis was 84 days and 52% of the events occurred within 100 days from AML diagnosis. Khorana and DIC score failed to stratify patients according to their thrombotic risk. Only history of a thrombotic event (p = 0.043), particularly VTE (p = 0.0053), platelet count above 100 × 10
Identifiants
pubmed: 35128571
doi: 10.1007/s00277-022-04770-6
pii: 10.1007/s00277-022-04770-6
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
855-867Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Khorana AA (2010) Venous Thromboembolism and Prognosis in Cancer. Thromb Res 125:490–493. https://doi.org/10.1016/j.thromres.2009.12.023
doi: 10.1016/j.thromres.2009.12.023
pubmed: 20097409
pmcid: 2878879
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy. J Thromb Haemost 5:632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x
doi: 10.1111/j.1538-7836.2007.02374.x
pubmed: 17319909
Falanga A, Russo L, Verzeroli C (2013) Mechanisms of Thrombosis in Cancer. Thromb Res 131(Suppl 1):S59-62. https://doi.org/10.1016/S0049-3848(13)70024-0
doi: 10.1016/S0049-3848(13)70024-0
pubmed: 23452745
Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA 293:715–722. https://doi.org/10.1001/jama.293.6.715
doi: 10.1001/jama.293.6.715
pubmed: 15701913
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of Cancer-Associated Venous Thrombosis. Blood 122:1712–1723. https://doi.org/10.1182/blood-2013-04-460121
doi: 10.1182/blood-2013-04-460121
pubmed: 23908465
Falanga A, Marchetti M, Vignoli A (2013) Coagulation and Cancer: Biological and Clinical Aspects. J Thromb Haemost 11:223–233. https://doi.org/10.1111/jth.12075
doi: 10.1111/jth.12075
pubmed: 23279708
White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T (2005) Incidence of Venous Thromboembolism in the Year before the Diagnosis of Cancer in 528,693 Adults. Arch Intern Med 165:1782–1787. https://doi.org/10.1001/archinte.165.15.1782
doi: 10.1001/archinte.165.15.1782
pubmed: 16087828
Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH (2006) Thromboembolism in Hospitalized Neutropenic Cancer Patients. J Clin Oncol 24:484–490. https://doi.org/10.1200/JCO.2005.03.8877
doi: 10.1200/JCO.2005.03.8877
pubmed: 16421425
Colombo R, Gallipoli P, Castelli R (2014) Thrombosis and Hemostatic Abnormalities in Hematological Malignancies. Clin Lymphoma Myeloma Leuk 14:441–450. https://doi.org/10.1016/j.clml.2014.05.003
doi: 10.1016/j.clml.2014.05.003
pubmed: 25018062
Chojnowski K, Wawfuyniak E, Treilinski J, Niewiarowska J, Cierniewski C (1999) Assessment of Coagulation Disorders in Patients with Acute Leukemia Before and After Cytostatic Treatment. Leuk Lymphoma 36:77–84. https://doi.org/10.3109/10428199909145951
doi: 10.3109/10428199909145951
pubmed: 10613452
Del Principe, M.I.; del principe, D.; Venditti, A. Thrombosis in Adult Patients with Acute Leukemia. Current Opinion in Oncology 2017, 29, 1, https://doi.org/10.1097/CCO.0000000000000402 .
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, Risk Factors, and Trends for Venous Thromboembolism among Hospitalized Cancer Patients. Cancer 110:2339–2346. https://doi.org/10.1002/cncr.23062
doi: 10.1002/cncr.23062
pubmed: 17918266
Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA, Yang D, Kantarjian H, Kroll MH (2015) A Retrospective Study of Venous Thromboembolism in Acute Leukemia Patients Treated at the University of Texas MD Anderson Cancer Center. Cancer Med 4:27–35. https://doi.org/10.1002/cam4.332
doi: 10.1002/cam4.332
pubmed: 25487644
Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K (2005) Symptomatic Venous Thromboembolism in Acute Leukemia Incidence, Risk Factors, and Impact on Prognosis. Thromb Res 115:59–64. https://doi.org/10.1016/j.thromres.2004.07.016
doi: 10.1016/j.thromres.2004.07.016
pubmed: 15567454
Lee Y-G, Kim I, Kwon J, Yoon SS, Park S, Song L, Yoon J-H, Shin S-H, Min W-S, Kim H-J (2015) Implications of Cytogenetics for Venous Thromboembolism in Acute Myeloid Leukaemia. Thromb Haemost 113:201–208. https://doi.org/10.1160/TH13-12-1020
doi: 10.1160/TH13-12-1020
pubmed: 25339605
Refaei M, Fernandes B, Brandwein J, Goodyear MD, Pokhrel A, Wu C (2016) Incidence of Catheter-Related Thrombosis in Acute Leukemia Patients: A Comparative, Retrospective Study of the Safety of Peripherally Inserted vs Centrally Inserted Central Venous Catheters. Ann Hematol 95:2057–2064. https://doi.org/10.1007/s00277-016-2798-4
doi: 10.1007/s00277-016-2798-4
pubmed: 27542955
Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, Gussoni G, Barbui T, Mannucci PM (2005) Incidence of Thrombotic Complications in Patients with Haematological Malignancies with Central Venous Catheters: A Prospective Multicentre Study. Br J Haematol 129:811–817. https://doi.org/10.1111/j.1365-2141.2005.05529.x
doi: 10.1111/j.1365-2141.2005.05529.x
pubmed: 15953009
Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E et al (2013) Infections Increase the Risk of Central Venous Catheter-Related Thrombosis in Adult Acute Myeloid Leukemia. Thromb Res 132:511–514. https://doi.org/10.1016/j.thromres.2013.08.007
doi: 10.1016/j.thromres.2013.08.007
pubmed: 24090605
De Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, Zini G, Pagano L, Sica S, Leone G (2005) The Risk of Thrombosis in Patients with Acute Leukemia: Occurrence of Thrombosis at Diagnosis and during Treatment. J Thromb Haemost 3:1985–1992. https://doi.org/10.1111/j.1538-7836.2005.01467.x
doi: 10.1111/j.1538-7836.2005.01467.x
pubmed: 16102104
Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano MR, Cascavilla N (2007) Symptomatic Venous Thromboembolism and Thrombophilic Status in Adult Acute Leukemia: A Single-Center Experience of 114 Patients at Diagnosis. Acta Haematol 117:215–220. https://doi.org/10.1159/000098700
doi: 10.1159/000098700
pubmed: 17237616
Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A (2006) Increased Risk of Venous Thromboembolism in Patients with Acute Leukaemia. Br J Cancer 94:200–202. https://doi.org/10.1038/sj.bjc.6602945
doi: 10.1038/sj.bjc.6602945
pubmed: 16421591
pmcid: 2361116
Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T (2009) Venous Thromboembolism in Patients with Acute Leukemia: Incidence, Risk Factors, and Effect on Survival. Blood 113:3911–3917. https://doi.org/10.1182/blood-2008-08-175745
doi: 10.1182/blood-2008-08-175745
pubmed: 19088376
pmcid: 2673120
Al-Ani F, Wang YP, Lazo-Langner A (2020) Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia. Thromb Haemost 120:322–328. https://doi.org/10.1055/s-0039-3400303
doi: 10.1055/s-0039-3400303
pubmed: 31893562
Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, Sakura T, Jimbo T, Handa H, Tsukamoto N et al (2007) Prevalence and Clinical Characteristics of Acute Myeloid Leukemia Associated with Disseminated Intravascular Coagulation. Int J Hematol 86:137–142. https://doi.org/10.1532/IJH97.06173
doi: 10.1532/IJH97.06173
pubmed: 17875527
Shen Y, Zhou X, Wang Z, Yang G, Jiang Y, Sun C, Wang J, Tong Y, Guo H (2011) Coagulation Profiles and Thromboembolic Events of Bortezomib plus Thalidomide and Dexamethasone Therapy in Newly Diagnosed Multiple Myeloma. Leuk Res 35:147–151. https://doi.org/10.1016/j.leukres.2010.08.007
doi: 10.1016/j.leukres.2010.08.007
pubmed: 20832859
Ahmed G, Nasir HG, Hall K, Weissmann L (2020) Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-Based Observational Experience. Cureus 12:e7883. https://doi.org/10.7759/cureus.7883
doi: 10.7759/cureus.7883
pubmed: 32489737
pmcid: 7255532
van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F et al (2020) The Khorana Score for Prediction of Venous Thromboembolism in Cancer Patients: An Individual Patient Data Meta-Analysis. J Thromb Haemost 18:1940–1951. https://doi.org/10.1111/jth.14824
doi: 10.1111/jth.14824
pubmed: 32336010
Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, Smit K, Büller HR, van Es N (2019) CAT-prediction collaborators The Khorana Score for Prediction of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis. Haematologica 104:1277–1287. https://doi.org/10.3324/haematol.2018.209114
doi: 10.3324/haematol.2018.209114
pubmed: 30606788
pmcid: 6545838
Mirza, A.-S.; Yun, S.; Al ali, N.; Shin, H.; O’Neil, J.; Elharake, M.; Schwartz, D.; Robinson, K.; Nowell, E.; Engle, G.; et al. Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single-Institution Experience. Thrombosis Journal 2019, 17, doi: https://doi.org/10.1186/s12959-019-0202-z .
Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, Löwenberg B, Leebeek FWG (2016) Disseminated Intravascular Coagulation at Diagnosis Is a Strong Predictor for Thrombosis in Acute Myeloid Leukemia. Blood 128:1854–1861. https://doi.org/10.1182/blood-2016-02-701094
doi: 10.1182/blood-2016-02-701094
pubmed: 27354723
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F et al (2012) Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood 120:2454–2465. https://doi.org/10.1182/blood-2012-03-420489
doi: 10.1182/blood-2012-03-420489
pubmed: 22740453
pmcid: 4425443
Cerrano M, Candoni A, Crisà E, Dubbini MV, D’Ardia S, Zannier ME, Boccadoro M, Audisio E, Bruno B, Ferrero D (2019) FLAI Induction Regimen in Elderly Patients with Acute Myeloid Leukemia. Leuk Lymphoma 60:3339–3340. https://doi.org/10.1080/10428194.2019.1620943
doi: 10.1080/10428194.2019.1620943
pubmed: 31159609
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA et al (2010) Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European LeukemiaNet. Blood 115:453–474. https://doi.org/10.1182/blood-2009-07-235358
doi: 10.1182/blood-2009-07-235358
pubmed: 19880497
Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BES, Wheatley K, Milligan D (2013) Optimization of Chemotherapy for Younger Patients with Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. J Clin Oncol 31:3360–3368. https://doi.org/10.1200/JCO.2012.47.4874
doi: 10.1200/JCO.2012.47.4874
pubmed: 23940227
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G et al (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377:454–464. https://doi.org/10.1056/NEJMoa1614359
doi: 10.1056/NEJMoa1614359
pubmed: 28644114
pmcid: 5754190
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR et al (2018) CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36:2684–2692. https://doi.org/10.1200/JCO.2017.77.6112
doi: 10.1200/JCO.2017.77.6112
pubmed: 30024784
pmcid: 6127025
Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E et al (2019) Randomized Trial Comparing Standard vs Sequential High-Dose Chemotherapy for Inducing Early CR in Adult AML. Blood Adv 3:1103–1117. https://doi.org/10.1182/bloodadvances.2018026625
doi: 10.1182/bloodadvances.2018026625
pubmed: 30948365
pmcid: 6457212
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and Validation of a Predictive Model for Chemotherapy-Associated Thrombosis. Blood 111:4902–4907. https://doi.org/10.1182/blood-2007-10-116327
doi: 10.1182/blood-2007-10-116327
pubmed: 18216292
pmcid: 2384124
O’brien RM (2007) A Caution Regarding Rules of Thumb for Variance Inflation Factors. Qual Quant 41:673–690. https://doi.org/10.1007/s11135-006-9018-6
doi: 10.1007/s11135-006-9018-6
Korn EL (1986) Censoring Distributions as a Measure of Follow-up in Survival Analysis. Stat Med 5:255–260. https://doi.org/10.1002/sim.4780050306
doi: 10.1002/sim.4780050306
pubmed: 3738291
Grambsch PM, Therneau TM (1994) Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika 81:515–526. https://doi.org/10.1093/biomet/81.3.515
doi: 10.1093/biomet/81.3.515
Curran D, Molenberghs G, Fayers PM, Machin D (1998) Incomplete Quality of Life Data in Randomized Trials: Missing Forms. Stat Med 17:697–709. https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7%3c697::aid-sim815%3e3.0.co;2-y
doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<697::aid-sim815>3.0.co;2-y
pubmed: 9549817
Buuren SV, Brand JPL, Groothuis-Oudshoorn CGM, Rubin DB (2006) Fully Conditional Specification in Multivariate Imputation. J Stat Comput Simul 76:1049–1064. https://doi.org/10.1080/10629360600810434
doi: 10.1080/10629360600810434
Toutenburg H, Rubin DB (1990) Multiple Imputation for Nonresponse in Surveys. Stat Pap 31:180–180. https://doi.org/10.1007/BF02924688
doi: 10.1007/BF02924688
Rickles FR, Falanga A (2001) Molecular Basis for the Relationship between Thrombosis and Cancer. Thromb Res 102:V215-224. https://doi.org/10.1016/s0049-3848(01)00285-7
doi: 10.1016/s0049-3848(01)00285-7
pubmed: 11516455
Rickles F, Falanga A, Montesinos P, Sanz M, Brenner B, Barbui T (2007) Bleeding and Thrombosis in Acute Leukemia: What Does the Future of Therapy Look Like? Thromb Res 120(Suppl 2):S99-106. https://doi.org/10.1016/S0049-3848(07)70137-8
doi: 10.1016/S0049-3848(07)70137-8
pubmed: 18023721
Barbui T, Falanga A (2001) Disseminated Intravascular Coagulation in Acute Leukemia. Semin Thromb Hemost 27:593–604. https://doi.org/10.1055/s-2001-18865
doi: 10.1055/s-2001-18865
pubmed: 11740683
Falanga A (1998) Mechanisms of Hypercoagulation in Malignancy and during Chemotherapy. Haemostasis 28(Suppl 3):50–60. https://doi.org/10.1159/000022405
doi: 10.1159/000022405
pubmed: 10069762
Lee AY, Levine MN (1999) The Thrombophilic State Induced by Therapeutic Agents in the Cancer Patient. Semin Thromb Hemost 25:137–145. https://doi.org/10.1055/s-2007-994915
doi: 10.1055/s-2007-994915
pubmed: 10357081
Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F et al (2006) A Clinical Outcome-Based Prospective Study on Venous Thromboembolism after Cancer Surgery: The @RISTOS Project. Ann Surg 243:89–95. https://doi.org/10.1097/01.sla.0000193959.44677.48
doi: 10.1097/01.sla.0000193959.44677.48
pubmed: 16371741
pmcid: 1449979
Connolly GC, Khorana AA (2010) Emerging Risk Stratification Approaches to Cancer-Associated Thrombosis: Risk Factors, Biomarkers and a Risk Score. Thromb Res 125(Suppl 2):S1-7. https://doi.org/10.1016/S0049-3848(10)00227-6
doi: 10.1016/S0049-3848(10)00227-6
pubmed: 20433985
Rosovsky RP, Kuter DJ (2005) Catheter-Related Thrombosis in Cancer Patients: Pathophysiology Diagnosis, and Management. Hematol Oncol Clin North Am 19:183–202. https://doi.org/10.1016/j.hoc.2004.09.007
doi: 10.1016/j.hoc.2004.09.007
pubmed: 15639113
Esmon CT (2005) The Interactions between Inflammation and Coagulation. Br J Haematol 131:417–430. https://doi.org/10.1111/j.1365-2141.2005.05753.x
doi: 10.1111/j.1365-2141.2005.05753.x
pubmed: 16281932
Geerts W (2014) Central Venous Catheter-Related Thrombosis. Hematology Am Soc Hematol Educ Program 2014:306–311. https://doi.org/10.1182/asheducation-2014.1.306
doi: 10.1182/asheducation-2014.1.306
pubmed: 25696870
Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F, Giordano C, Grimaldi F, Zacheo I, Raimondo M et al (2019) A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison. Clin Lymphoma Myeloma Leuk 19:e184–e194. https://doi.org/10.1016/j.clml.2018.12.008
doi: 10.1016/j.clml.2018.12.008
pubmed: 30704933
Evans RS, Sharp JH, Linford LH, Lloyd JF, Woller SC, Stevens SM, Elliott CG, Tripp JS, Jones SS, Weaver LK (2013) Reduction of Peripherally Inserted Central Catheter-Associated DVT. Chest 143:627–633. https://doi.org/10.1378/chest.12-0923
doi: 10.1378/chest.12-0923
pubmed: 22878346
Chopra V, Anand S, Hickner A, Buist M, Rogers MA, Saint S, Flanders SA (2013) Risk of Venous Thromboembolism Associated with Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis. Lancet 382:311–325. https://doi.org/10.1016/S0140-6736(13)60592-9
doi: 10.1016/S0140-6736(13)60592-9
pubmed: 23697825
Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, Young A, De Cicco M, Biffi R, van Rooden CJ et al (2011) Risk Factors for Catheter-Related Thrombosis (CRT) in Cancer Patients: A Patient-Level Data (IPD) Meta-Analysis of Clinical Trials and Prospective Studies. J Thromb Haemost 9:312–319. https://doi.org/10.1111/j.1538-7836.2010.04126.x
doi: 10.1111/j.1538-7836.2010.04126.x
pubmed: 21040443
pmcid: 4282796
Itkin M, Mondshein JI, Stavropoulos SW, Shlansky-Goldberg RD, Soulen MC, Trerotola SO (2014) Peripherally Inserted Central Catheter Thrombosis-Reverse Tapered versus Nontapered Catheters: A Randomized Controlled Study. J Vasc Interv Radiol 25:85-91.e1. https://doi.org/10.1016/j.jvir.2013.10.009
doi: 10.1016/j.jvir.2013.10.009
pubmed: 24268631
McKeown C, Ricciuti A, Agha M, Raptis A, Hou J-Z, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A et al (2021) A Prospective Study of the Use of Central Venous Catheters in Patients Newly Diagnosed with Acute Myeloid Leukemia Treated with Induction Chemotherapy. Support Care Cancer. https://doi.org/10.1007/s00520-021-06339-x
doi: 10.1007/s00520-021-06339-x
pubmed: 34562168
Johansson E, Hammarskjöld F, Lundberg D, Arnlind MH (2013) Advantages and Disadvantages of Peripherally Inserted Central Venous Catheters (PICC) Compared to Other Central Venous Lines: A Systematic Review of the Literature. Acta Oncol 52:886–892. https://doi.org/10.3109/0284186X.2013.773072
doi: 10.3109/0284186X.2013.773072
pubmed: 23472835
Fang S, Yang J, Song L, Jiang Y, Liu Y (2017) Comparison of Three Types of Central Venous Catheters in Patients with Malignant Tumor Receiving Chemotherapy. Patient Prefer Adherence 11:1197–1204. https://doi.org/10.2147/PPA.S142556
doi: 10.2147/PPA.S142556
pubmed: 28744109
pmcid: 5513891
Yi X, Chen J, Li J, Feng L, Wang Y, Zhu J-A, Shen E, Hu B (2014) Risk Factors Associated with PICC-Related Upper Extremity Venous Thrombosis in Cancer Patients. J Clin Nurs 23:837–843. https://doi.org/10.1111/jocn.12227
doi: 10.1111/jocn.12227
pubmed: 23710585
Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M et al (2012) Prevention of Venous Thromboembolism in Patients with Cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1. Thromb Res 129:e171–e176. https://doi.org/10.1016/j.thromres.2011.09.002
doi: 10.1016/j.thromres.2011.09.002
pubmed: 21962722
Lee E-J, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, Gore S et al (2015) Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clin Lymphoma Myeloma Leuk 15:766-770.e4. https://doi.org/10.1016/j.clml.2015.07.637
doi: 10.1016/j.clml.2015.07.637
pubmed: 26363982
pmcid: 4663156
Couban, S.; Goodyear, M.; Burnell, M.; Dolan, S.; Wasi, P.; Barnes, D.; Macleod, D.; Burton, E.; Andreou, P.; Anderson, D.R. Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter-Associated Thrombosis in Patients with Cancer. Journal of Clinical Oncology 2005, 4063–4069.
Niers TMH, Nisio MD, Klerk CPW, Baarslag HJ, Büller HR, Biemond BJ (2007) Prevention of Catheter-Related Venous Thrombosis with Nadroparin in Patients Receiving Chemotherapy for Hematologic Malignancies: A Randomized, Placebo-Controlled Study. J Thromb Haemost 5:1878–1882. https://doi.org/10.1111/j.1538-7836.2007.02660.x
doi: 10.1111/j.1538-7836.2007.02660.x
pubmed: 17723127
Reed DR, Nicolais MC, Orellana-Noia VM, Minkin SJ, Morris AL, Maitland HS, Keng MK (2018) Venous Thromboembolism Events and Prophylaxis in Patients with Acute Myeloid Leukemia. Blood 132:5066–5066. https://doi.org/10.1182/blood-2018-99-112507
doi: 10.1182/blood-2018-99-112507